These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 18425392)

  • 1. Dual anti-cancer effects of weekly intraperitoneal docetaxel in treatment of advanced gastric cancer patients with peritoneal carcinomatosis: a feasibility and pharmacokinetic study.
    Fushida S; Kinoshita J; Yagi Y; Funaki H; Kinami S; Ninomiya I; Fujimura T; Nishimura G; Kayahara M; Ohta T
    Oncol Rep; 2008 May; 19(5):1305-10. PubMed ID: 18425392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics.
    Morgan RJ; Doroshow JH; Synold T; Lim D; Shibata S; Margolin K; Schwarz R; Leong L; Somlo G; Twardowski P; Yen Y; Chow W; Lin P; Paz B; Chu D; Frankel P; Stalter S
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5896-901. PubMed ID: 14676112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility study of S-1 and intraperitoneal docetaxel combination chemotherapy for gastric cancer with peritoneal dissemination.
    Fujiwara Y; Nishida T; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Yamamoto K; Moon JH; Mori M; Doki Y
    Anticancer Res; 2010 Apr; 30(4):1335-9. PubMed ID: 20530449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination.
    Fujiwara Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Okada K; Mori M; Doki Y
    Ann Surg Oncol; 2011 Dec; 18(13):3726-31. PubMed ID: 21584835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
    Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination.
    Fujiwara Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Mori M; Doki Y
    J Surg Oncol; 2012 Jan; 105(1):38-42. PubMed ID: 21882194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility and efficacy of preoperative chemotherapy with docetaxel, cisplatin and S-1 in gastric cancer patients with para-aortic lymph node metastases.
    Fushida S; Fujimura T; Oyama K; Yagi Y; Kinoshita J; Ohta T
    Anticancer Drugs; 2009 Sep; 20(8):752-6. PubMed ID: 19543076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of docetaxel, cisplatin and S-1 in patients with advanced gastric cancer.
    Hironaka S; Yamazaki K; Taku K; Yokota T; Shitara K; Kojima T; Ueda S; Machida N; Muro K; Boku N
    Jpn J Clin Oncol; 2010 Nov; 40(11):1014-20. PubMed ID: 20603245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic advantage of intraperitoneal injection of docetaxel in the treatment for peritoneal dissemination of cancer in mice.
    Shimada T; Nomura M; Yokogawa K; Endo Y; Sasaki T; Miyamoto K; Yonemura Y
    J Pharm Pharmacol; 2005 Feb; 57(2):177-81. PubMed ID: 15720780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: Selection for cytoreductive surgery.
    Yonemura Y; Endou Y; Shinbo M; Sasaki T; Hirano M; Mizumoto A; Matsuda T; Takao N; Ichinose M; Mizuno M; Miura M; Ikeda M; Ikeda S; Nakajima G; Yonemura J; Yuuba T; Masuda S; Kimura H; Matsuki N
    J Surg Oncol; 2009 Sep; 100(4):311-6. PubMed ID: 19697437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of intravenous (IV) docetaxel and intraperitoneal (IP) oxaliplatin in recurrent ovarian and fallopian tube cancer.
    Taylor SE; Li R; Petschauer JS; Donovan H; O'Neal S; Keeler AW; Zamboni WC; Edwards RP; Zorn KK
    Gynecol Oncol; 2015 Sep; 138(3):548-53. PubMed ID: 26111788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant treatment of gastric cancer with peritoneal dissemination.
    Yonemura Y; Bandou E; Sawa T; Yoshimitsu Y; Endou Y; Sasaki T; Sugarbaker PH
    Eur J Surg Oncol; 2006 Aug; 32(6):661-5. PubMed ID: 16621433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I dose-escalating study of 24-h continuous infusion of 5-fluorouracil in combination with weekly docetaxel and cisplatin in patients with advanced gastric cancer.
    Wang B; Zhang W; Hong X; Guo Y; Li J
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):213-8. PubMed ID: 18343924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bi-weekly docetaxel in the adjuvant treatment of node-positive or high-risk breast cancer patients: phase I study of the Shiga Breast Cancer Study Group.
    Abe H; Ogawa H; Okino T; Kato M; Sako H; Sano H; Shimomatsuya T; Suwa H; Higashide S
    Breast Cancer; 2009; 16(1):37-41. PubMed ID: 18493840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of bi-weekly docetaxel for recurrent or advanced gastric cancer patients whose disease progressed by prior chemotherapy.
    Kimura Y; Yano H; Taniguchi H; Iwazawa T; Danno K; Kagara N; Kanoh T; Ohnishi T; Tono T; Nakano Y; Monden T; Imaoka S
    Jpn J Clin Oncol; 2011 Jun; 41(6):747-51. PubMed ID: 21498408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer.
    Rino Y; Takanashi Y; Yukawa N; Saeki H; Wada H; Kanari M; Yamada R; Satoh T; Yamamoto N; Imada T
    Anticancer Res; 2006; 26(2B):1455-62. PubMed ID: 16619558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel-loaded thermoresponsive conjugated linoleic acid-incorporated poloxamer hydrogel for the suppression of peritoneal metastasis of gastric cancer.
    Bae WK; Park MS; Lee JH; Hwang JE; Shim HJ; Cho SH; Kim DE; Ko HM; Cho CS; Park IK; Chung IJ
    Biomaterials; 2013 Jan; 34(4):1433-41. PubMed ID: 23174142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis.
    Fushida S; Kinoshita J; Kaji M; Hirono Y; Goda F; Yagi Y; Oyama K; Sudo Y; Watanabe Y; Fujimura T;
    Cancer Chemother Pharmacol; 2013 May; 71(5):1265-72. PubMed ID: 23423490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of weekly docetaxel with a 4-weekly cisplatin administration in patients with advanced gastric carcinoma.
    Polyzos A; Syrigos K; Stergiou J; Panopoulos C; Potamianou A; Vamvakas L; Georgoulias V
    Cancer Chemother Pharmacol; 2005 May; 55(5):466-70. PubMed ID: 15660272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effectiveness of intraperitoneal chemotherapy using new-aged drugs for the peritoneal dissemination of gastric cancer].
    Fushida S; Fujita H; Kinami S; Ninomiya I; Fujimura T; Nishimura G; Ohta T
    Gan To Kagaku Ryoho; 2005 Oct; 32(11):1691-4. PubMed ID: 16315911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.